Advancements in Managing Anthracycline-Induced Cardiotoxicity: Insights from Interventional Clinical Trials

Mei Zhao,1 Xiaohong Zhang,1 Dongyang Zhou,2 Junxian Song3– 5 1Department of Pharmacy, Peking University People’s Hospital, Beijing, People’s Republic of China; 2Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK; 3Department of Cardiology,...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhao M, Zhang X, Zhou D, Song J
Format: Article
Language:English
Published: Dove Medical Press 2025-01-01
Series:Open Access Journal of Clinical Trials
Subjects:
Online Access:https://www.dovepress.com/advancements-in-managing-anthracycline-induced-cardiotoxicity-insights-peer-reviewed-fulltext-article-OAJCT
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832577645742653440
author Zhao M
Zhang X
Zhou D
Song J
author_facet Zhao M
Zhang X
Zhou D
Song J
author_sort Zhao M
collection DOAJ
description Mei Zhao,1 Xiaohong Zhang,1 Dongyang Zhou,2 Junxian Song3– 5 1Department of Pharmacy, Peking University People’s Hospital, Beijing, People’s Republic of China; 2Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK; 3Department of Cardiology, Peking University People’s Hospital, Beijing, People’s Republic of China; 4Beijing Key Laboratory of Early Prediction and Intervention of Acute Myocardial Infarction, Peking University People’s Hospital, Beijing, People’s Republic of China; 5Center for Cardiovascular Translational Research, Peking University People’s Hospital, Beijing, People’s Republic of ChinaCorrespondence: Junxian Song, Department of Cardiology, Peking University People’s Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, People’s Republic of China, Email sjx221@163.comPurpose: Anthracycline-induced cardiotoxicity (AIC) is a significant complication in cancer treatment, impacting long-term health outcomes. This study aimed to evaluate interventional clinical trials targeting AIC and identify effective strategies.Methods: We reviewed clinical trials on AIC from International Clinical Trial Registration Platform (ICTRP), focusing on intervention strategies. We assessed the publication status and effectiveness of cardioprotective agents, monitoring techniques, and exercise interventions.Results: A total of 100 trials were identified, with 35% published. Most studies were conducted in the United States, China, and Italy, highlighting geographical disparities. Effective interventions included dexrazoxane for primary prevention, ACEI/ARB combination with β blockers for long-term cardioprotection. Advanced monitoring techniques, including global longitudinal strain (GLS)-guided echocardiography, cardiac magnetic resonance (CMR) and novel biomarkers (cfDNA, microRNA), showed promise in early AIC detection. Exercise interventions demonstrated significant cardiovascular benefits.Conclusion: Cardioprotective agents, early detection methods, and exercise interventions are key to managing AIC. Dexrazoxane and ACEI/ARB combination with β blockers are promising. Exercise interventions can improve cardiovascular health and reduce AIC risk. Larger trials with long-term follow-up are essential for refining these strategies.Keywords: anthracycline-induced cardiotoxicity, clinical trials, cardiovascular toxicity, cancer therapy safety
format Article
id doaj-art-03e4b71e3ee84a939358ec5d8116bf6a
institution Kabale University
issn 1179-1519
language English
publishDate 2025-01-01
publisher Dove Medical Press
record_format Article
series Open Access Journal of Clinical Trials
spelling doaj-art-03e4b71e3ee84a939358ec5d8116bf6a2025-01-30T18:07:17ZengDove Medical PressOpen Access Journal of Clinical Trials1179-15192025-01-01Volume 1711499715Advancements in Managing Anthracycline-Induced Cardiotoxicity: Insights from Interventional Clinical TrialsZhao MZhang XZhou DSong JMei Zhao,1 Xiaohong Zhang,1 Dongyang Zhou,2 Junxian Song3– 5 1Department of Pharmacy, Peking University People’s Hospital, Beijing, People’s Republic of China; 2Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK; 3Department of Cardiology, Peking University People’s Hospital, Beijing, People’s Republic of China; 4Beijing Key Laboratory of Early Prediction and Intervention of Acute Myocardial Infarction, Peking University People’s Hospital, Beijing, People’s Republic of China; 5Center for Cardiovascular Translational Research, Peking University People’s Hospital, Beijing, People’s Republic of ChinaCorrespondence: Junxian Song, Department of Cardiology, Peking University People’s Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, People’s Republic of China, Email sjx221@163.comPurpose: Anthracycline-induced cardiotoxicity (AIC) is a significant complication in cancer treatment, impacting long-term health outcomes. This study aimed to evaluate interventional clinical trials targeting AIC and identify effective strategies.Methods: We reviewed clinical trials on AIC from International Clinical Trial Registration Platform (ICTRP), focusing on intervention strategies. We assessed the publication status and effectiveness of cardioprotective agents, monitoring techniques, and exercise interventions.Results: A total of 100 trials were identified, with 35% published. Most studies were conducted in the United States, China, and Italy, highlighting geographical disparities. Effective interventions included dexrazoxane for primary prevention, ACEI/ARB combination with β blockers for long-term cardioprotection. Advanced monitoring techniques, including global longitudinal strain (GLS)-guided echocardiography, cardiac magnetic resonance (CMR) and novel biomarkers (cfDNA, microRNA), showed promise in early AIC detection. Exercise interventions demonstrated significant cardiovascular benefits.Conclusion: Cardioprotective agents, early detection methods, and exercise interventions are key to managing AIC. Dexrazoxane and ACEI/ARB combination with β blockers are promising. Exercise interventions can improve cardiovascular health and reduce AIC risk. Larger trials with long-term follow-up are essential for refining these strategies.Keywords: anthracycline-induced cardiotoxicity, clinical trials, cardiovascular toxicity, cancer therapy safetyhttps://www.dovepress.com/advancements-in-managing-anthracycline-induced-cardiotoxicity-insights-peer-reviewed-fulltext-article-OAJCTanthracycline-induced cardiotoxicityclinical trialscardiovascular toxicitycancer therapy safety
spellingShingle Zhao M
Zhang X
Zhou D
Song J
Advancements in Managing Anthracycline-Induced Cardiotoxicity: Insights from Interventional Clinical Trials
Open Access Journal of Clinical Trials
anthracycline-induced cardiotoxicity
clinical trials
cardiovascular toxicity
cancer therapy safety
title Advancements in Managing Anthracycline-Induced Cardiotoxicity: Insights from Interventional Clinical Trials
title_full Advancements in Managing Anthracycline-Induced Cardiotoxicity: Insights from Interventional Clinical Trials
title_fullStr Advancements in Managing Anthracycline-Induced Cardiotoxicity: Insights from Interventional Clinical Trials
title_full_unstemmed Advancements in Managing Anthracycline-Induced Cardiotoxicity: Insights from Interventional Clinical Trials
title_short Advancements in Managing Anthracycline-Induced Cardiotoxicity: Insights from Interventional Clinical Trials
title_sort advancements in managing anthracycline induced cardiotoxicity insights from interventional clinical trials
topic anthracycline-induced cardiotoxicity
clinical trials
cardiovascular toxicity
cancer therapy safety
url https://www.dovepress.com/advancements-in-managing-anthracycline-induced-cardiotoxicity-insights-peer-reviewed-fulltext-article-OAJCT
work_keys_str_mv AT zhaom advancementsinmanaginganthracyclineinducedcardiotoxicityinsightsfrominterventionalclinicaltrials
AT zhangx advancementsinmanaginganthracyclineinducedcardiotoxicityinsightsfrominterventionalclinicaltrials
AT zhoud advancementsinmanaginganthracyclineinducedcardiotoxicityinsightsfrominterventionalclinicaltrials
AT songj advancementsinmanaginganthracyclineinducedcardiotoxicityinsightsfrominterventionalclinicaltrials